- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06244628
Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD
Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD After Allogeneic Hematopoietic Stem Cell Transplantation
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Kailin Xu, MD.,PD.
- Phone Number: 15162166166
- Email: lihmd@163.com
Study Locations
-
-
Jiangsu
-
Xuzhou, Jiangsu, China, 221000
- Recruiting
- Kailin Xu
-
Contact:
- Kailin Xu, M.D., Ph.D.
- Phone Number: 15162166166
- Email: lihmd@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged ≥18 years who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), regardless of gender.
- Those with persistent manifestations of chronic graft-versus-host disease (cGVHD) and suitable for systemic treatment.
- Previously received at least 1 but not more than 5 lines of systemic treatment for cGVHD.
- Corticosteroid therapy dose stable for the two weeks before screening; or, if taking prednisone or an equivalent dose of other corticosteroids at a dose >0.5mg/kg/day for four weeks, with ongoing cGVHD manifestations and no improvement; or, if two attempts to taper steroids to a lower dose have failed, and it is necessary to increase the prednisone dose to >0.25mg/kg/day or an equivalent dose.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score: 0~1.
Anticipated survival of more than 12 months.
General criteria:
- Serum pregnancy test negative for women of childbearing age during the screening period.
- Sexually active women of childbearing age participating in this study must agree to contraception during the trial and after the last dose of medication.
Exclusion Criteria:
- Patients who have received experimental treatment for systemic cGVHD within the 28 days prior to enrollment, which was effective and could completely alleviate immunosuppression.
Blood cancer relapse (according to the corresponding criteria for relapse of the primary blood cancer) or post-transplant lymphoproliferative disease at the time of screening.
Laboratory tests:
- Absolute neutrophil count (ANC) <1.5×10^9/L (excluding GVHD as the cause).
- Platelet count <50×10^9/L (excluding GVHD as the cause).
- Alanine aminotransferase (ALT) >3 times the upper limit of normal (ULN), aspartate aminotransferase (AST) >3×ULN (excluding GVHD as the cause).
- Total bilirubin (TBIL) >1.5×ULN (excluding GVHD as the cause).
Creatinine clearance CrCl <60 mL/min (Cockcroft-Gault formula).
General criteria:
- Pregnant or lactating women.
History of serious illness or other evidence indicating a serious illness, or any other condition that the investigator believes may make the subject unsuitable for this study.
- History of severe cardiovascular disease [New York Heart Association (NYHA) functional class III or IV], including but not limited to ventricular arrhythmias requiring clinical intervention, uncontrolled hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg); within 6 months prior to enrollment, there is unstable angina, acute coronary syndrome, congestive heart failure, stroke, or other cardiovascular events of class III or above; at screening, NYHA functional class ≥II or left ventricular ejection fraction (LVEF) <50% on echocardiography.
- Unable to take oral medications, with severe (NCI CTCAE v5.0 ≥ grade 3) chronic gastrointestinal dysfunction, the presence of malabsorption syndrome, or any other condition affecting gastrointestinal absorption.
- History of clear neurological or psychiatric disorders (including epilepsy or dementia), currently suffering from psychiatric disorders, or judged by the investigator to be non-compliant and unsuitable for participation in the study.
- History of other severe (NCI CTCAE v5.0 ≥ grade 3) systemic diseases, deemed unsuitable for participation in the clinical trial by the investigator.
- Other circumstances in which the investigator deems it inappropriate to participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Iguratimod
Oral administration of Iguratimod, 25mg twice daily.
|
Oral administration of Iguratimod, 25mg twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Baseline up to 60 days after taking Iguratimod
|
Adverse events assessed according to NCI-CTCAE v5.0
|
Baseline up to 60 days after taking Iguratimod
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
complete response (CR)
Time Frame: Month 1, 2, 3 and 4
|
Assessment of CR at Month 1, 2, 3 and 4. According to the CHRONIC GVHD ACTIVITY ASSESSMENT - CLINICIAN recorded in NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV.
The 2014 Response Criteria Working Group report.
(Biol Blood Marrow Transplant.
2015 Jun;21(6):984-99.)
|
Month 1, 2, 3 and 4
|
partial response (PR)
Time Frame: Month 1, 2, 3 and 4
|
Assessment of CR at Month 1, 2, 3 and 4. According to the CHRONIC GVHD ACTIVITY ASSESSMENT - CLINICIAN recorded in NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV.
The 2014 Response Criteria Working Group report.
(Biol Blood Marrow Transplant.
2015 Jun;21(6):984-99.)
|
Month 1, 2, 3 and 4
|
stable disease (SD)
Time Frame: Month 1, 2, 3 and 4
|
Assessment of SD at Month 1, 2, 3 and 4. According to the CHRONIC GVHD ACTIVITY ASSESSMENT - CLINICIAN recorded in NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV.
The 2014 Response Criteria Working Group report.
(Biol Blood Marrow Transplant.
2015 Jun;21(6):984-99.)
|
Month 1, 2, 3 and 4
|
progressed disease (PD)
Time Frame: Month 1, 2, 3 and 4
|
Assessment of PD at Month 1, 2, 3 and 4. According to the CHRONIC GVHD ACTIVITY ASSESSMENT - CLINICIAN recorded in NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV.
The 2014 Response Criteria Working Group report.
(Biol Blood Marrow Transplant.
2015 Jun;21(6):984-99.)
|
Month 1, 2, 3 and 4
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- XYFY2023-KL371-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on cGVHD
-
Chinese PLA General HospitalRecruiting
-
Peking University People's HospitalNot yet recruiting
-
Dana-Farber Cancer InstituteCompletedGraft vs Host Disease | Chronic Graft vs Host Disease | cGVHDUnited States
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRecruitingRefractory Chronic Graft Versus Host Disease (cGVHD)Belgium
-
Abbisko Therapeutics Co, LtdRecruiting
-
Incyte CorporationRecruiting
-
AmgenTerminatedChronic Graft Versus Host Disease cGVHDUnited States, Japan, France, Belgium
-
AmgenCompletedChronic Graft-versus-host Disease (cGVHD)United States
-
AmgenCompletedChronic Graft-versus-Host Disease (cGVHD)Australia
Clinical Trials on Iguratimod
-
Jiangsu Simcere Pharmaceutical Co., Ltd.UnknownRheumatoid ArthritisChina
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Completed
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Recruiting
-
Eisai Co., Ltd.CompletedRheumatoid ArthritisJapan
-
Peking University People's HospitalNot yet recruitingHand Osteoarthritis | Inflammatory Arthritis
-
Peking Union Medical College HospitalUnknown
-
Peking University People's HospitalNot yet recruitingImmune ThrombocytopeniaChina
-
Nanfang Hospital of Southern Medical UniversityJiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruitingRheumatoid Arthritis